🎉 M&A multiples are live!
Check it out!

Dimerix Valuation Multiples

Discover revenue and EBITDA valuation multiples for Dimerix and similar public comparables like Armata Pharmaceuticals, Vivoryon Therapeutics, and Pharming.

Dimerix Overview

About Dimerix

Dimerix Ltd is a biopharmaceutical company developing new therapies in areas with unmet medical needs. The company is developing four product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for COPD, as well as the proprietary ReceptorHIT assay technology. It pursues new product concepts and applies deep scientific knowledge to the discovery of products from early-stage development through to commercialisation. Dimerix products will target multiple territories. The Group has only operated in one Segment, being investment in research and development of biopharmaceutical drugs.


Founded

1975

HQ

Australia
Employees

14

Website

dimerix.com

Financials

LTM Revenue $6.3M

LTM EBITDA -$14.3M

EV

$163M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Dimerix Financials

As of September 2025, Dimerix reported last 12-month revenue of $6.3M and EBITDA of -$14.3M.

In the same period, Dimerix achieved -$6.1M in LTM net income.

See Dimerix valuation multiples based on analyst estimates

Dimerix P&L

In the most recent fiscal year, Dimerix reported revenue of $3.6M and EBITDA of -$20.8M.

Dimerix expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Dimerix valuation multiples based on analyst estimates
LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $6.3M XXX $3.6M XXX XXX XXX
Gross Profit n/a XXX $3.6M XXX XXX XXX
Gross Margin n/a XXX 100% XXX XXX XXX
EBITDA -$14.3M XXX -$20.8M XXX XXX XXX
EBITDA Margin -228% XXX -571% XXX XXX XXX
EBIT -$14.5M XXX -$20.8M XXX XXX XXX
EBIT Margin -231% XXX -573% XXX XXX XXX
Net Profit -$6.1M XXX -$8.6M XXX XXX XXX
Net Margin -97% XXX -237% XXX XXX XXX
Net Debt XXX XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Dimerix Stock Performance

Dimerix has current market cap of AUD 318M (or $207M), and EV of AUD 250M (or $163M).

Market Cap Evolution

Dimerix Stock Data

As of October 17, 2025, Dimerix's stock price is AUD 1 (or $0).

See Dimerix trading valuation data
EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$163M $207M XXX XXX XXX XXX $-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Dimerix Valuation Multiples

Dimerix's trades at 83.4x EV/Revenue multiple, and -8.8x EV/EBITDA.

See valuation multiples for Dimerix and 15K+ public comps

Dimerix Financial Valuation Multiples

As of October 17, 2025, Dimerix has market cap of $207M and EV of $163M.

Equity research analysts estimate Dimerix's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Dimerix has a P/E ratio of -34.2x.

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $207M XXX $207M XXX XXX XXX
EV (current) $163M XXX $163M XXX XXX XXX
EV/Revenue 26.0x XXX 83.4x XXX XXX XXX
EV/EBITDA -11.4x XXX -8.8x XXX XXX XXX
EV/EBIT -11.2x XXX -8.7x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E -34.2x XXX -21.0x XXX XXX XXX
EV/FCF 5.9x XXX 15.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Dimerix Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Dimerix Margins & Growth Rates

Dimerix's last 12 month revenue growth is 247%

Dimerix's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.7M for the same period.

Dimerix's rule of 40 is -705% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Dimerix's rule of X is 389% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Dimerix and other 15K+ public comps

Dimerix Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 247% XXX 281% XXX XXX XXX
EBITDA Margin -228% XXX -952% XXX XXX XXX
EBITDA Growth -179% XXX n/a XXX XXX XXX
Rule of 40 -705% XXX -705% XXX XXX XXX
Bessemer Rule of X XXX XXX 389% XXX XXX XXX
Revenue per Employee XXX XXX $0.3M XXX XXX XXX
Opex per Employee XXX XXX $1.7M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 489% XXX XXX XXX
Opex to Revenue XXX XXX 673% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Dimerix Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Dimerix M&A and Investment Activity

Dimerix acquired  XXX companies to date.

Last acquisition by Dimerix was  XXXXXXXX, XXXXX XXXXX XXXXXX . Dimerix acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Dimerix

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About Dimerix

When was Dimerix founded? Dimerix was founded in 1975.
Where is Dimerix headquartered? Dimerix is headquartered in Australia.
How many employees does Dimerix have? As of today, Dimerix has 14 employees.
Is Dimerix publicy listed? Yes, Dimerix is a public company listed on ASX.
What is the stock symbol of Dimerix? Dimerix trades under DXB ticker.
When did Dimerix go public? Dimerix went public in 1993.
Who are competitors of Dimerix? Similar companies to Dimerix include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Dimerix? Dimerix's current market cap is $207M
What is the current revenue of Dimerix? Dimerix's last 12 months revenue is $6.3M.
What is the current revenue growth of Dimerix? Dimerix revenue growth (NTM/LTM) is 247%.
What is the current EV/Revenue multiple of Dimerix? Current revenue multiple of Dimerix is 26.0x.
Is Dimerix profitable? Yes, Dimerix is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Dimerix? Dimerix's last 12 months EBITDA is -$14.3M.
What is Dimerix's EBITDA margin? Dimerix's last 12 months EBITDA margin is -228%.
What is the current EV/EBITDA multiple of Dimerix? Current EBITDA multiple of Dimerix is -11.4x.
What is the current FCF of Dimerix? Dimerix's last 12 months FCF is $27.6M.
What is Dimerix's FCF margin? Dimerix's last 12 months FCF margin is 441%.
What is the current EV/FCF multiple of Dimerix? Current FCF multiple of Dimerix is 5.9x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.